COMPUGEN LTDCGENEarnings & Financial Report
Nasdaq · biotechnology
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big compan...
CGEN Q1 2024 Key Financial Metrics
売上高
$2.6M
粗利益
$457.0K
営業利益
N/A
純利益
$7.3M
粗利益率
17.9%
営業利益率
N/A
純利益率
284.0%
前年比成長
N/A
資金フロー
COMPUGEN LTD Q1 2024 Financial Summary
COMPUGEN LTD reported revenue of $2.6M for Q1 2024, with a net profit of $7.3M (284.0% margin). Cost of goods sold was $2.1M.
Key Financial Metrics
| Total Revenue | $2.6M |
|---|---|
| Net Profit | $7.3M |
| Gross Margin | 17.9% |
| Operating Margin | N/A |
| Report Period | Q1 2024 |
損益計算書
| Q1 2024 | |
|---|---|
| 売上高 | $2.6M |
| 前年比成長 | N/A |
貸借対照表
| Q1 2024 | |
|---|---|
| 総資産 | $121.3M |
| 総負債 | $55.8M |
| 株主資本 | $65.6M |
キャッシュフロー
No data available for this period